Spots Global Cancer Trial Database for total marrow irradiation
Every month we try and update this database with for total marrow irradiation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma | NCT02043860 | Multiple Myelom... | Total Marrow Ir... Autologous Tran... Melphalan Filgrastim (G-C... | 18 Years - 75 Years | University of Illinois at Chicago | |
| Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant | NCT02333162 | Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Hemat... | Fludarabine Pho... Melphalan Intensity-Modul... Total Marrow Ir... Allogeneic Hema... Peripheral Bloo... Allogeneic Bone... Tacrolimus Mycophenolate M... Laboratory Biom... | 18 Years - 75 Years | University of Chicago | |
| Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant | NCT02333162 | Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Hemat... | Fludarabine Pho... Melphalan Intensity-Modul... Total Marrow Ir... Allogeneic Hema... Peripheral Bloo... Allogeneic Bone... Tacrolimus Mycophenolate M... Laboratory Biom... | 18 Years - 75 Years | University of Chicago | |
| IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT | NCT03696537 | Acute Myeloid L... Chronic Myeloid... Acute Lymphocyt... Myelodysplastic... | Fludarabine Total Marrow Ir... | 18 Years - 65 Years | Indiana University | |
| Total Marrow Irradiation With Volumetric Arc Therapy for Patients Unfit for a 12 Gy TBI | NCT03262220 | Haematological ... | Volumetric Arc ... | 40 Years - 80 Years | University Hospital, Geneva | |
| A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies | NCT05201183 | Acute Myeloid L... Chronic Myeloid... Acute Lymphocyt... Myelodysplastic... | Fludarabine + T... | 18 Years - | Indiana University | |
| Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Relapsed or Refractory Multiple Myeloma (BMT-03) | NCT02043847 | Multiple Myelom... Multiple Myelom... | Total Marrow Ir... Melphalan Filgrastim (G-C... Autologous tran... Total Marrow Ir... Melphalan Filgrastim (G-C... Autologous tran... Total Marrow Ir... Melphalan Filgrastim (G-C... Autologous tran... | 18 Years - 75 Years | University of Illinois at Chicago | |
| Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma | NCT01163357 | Autologous Hema... Loss of Chromos... Plasma Cell Leu... Recurrent Plasm... Refractory Plas... | bortezomib fludarabine pho... melphalan total marrow ir... tacrolimus sirolimus peripheral bloo... laboratory biom... | 18 Years - 70 Years | City of Hope Medical Center | |
| Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome | NCT03494569 | Acute Lymphobla... Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Hematopoietic C... Minimal Residua... Myelodysplastic... Secondary Acute... | Fludarabine Laboratory Biom... Melphalan Total Marrow Ir... | 12 Years - | City of Hope Medical Center | |
| 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome | NCT05139004 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... Secondary Acute... | Allogeneic Hema... Basiliximab Fludarabine Pho... Indium In 111-D... Melphalan Palifermin Total Lymphoid ... Total Marrow Ir... Yttrium Y 90 Ba... | 60 Years - | City of Hope Medical Center | |
| 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome | NCT05139004 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... Secondary Acute... | Allogeneic Hema... Basiliximab Fludarabine Pho... Indium In 111-D... Melphalan Palifermin Total Lymphoid ... Total Marrow Ir... Yttrium Y 90 Ba... | 60 Years - | City of Hope Medical Center | |
| Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies | NCT02129582 | Acute Myeloid L... Hematologic Mal... Acute Lymphocyt... Non Hodgkin Lym... Hodgkin Lymphom... Multiple Myelom... Myelodysplastic... Chronic Lymphoc... Chronic Myeloid... Myelofibrosis Myeloproliferat... | total marrow ir... fludarabine pho... busulfan myeloid progeni... anti-thymocyte ... tacrolimus methotrexate laboratory biom... | 18 Years - 75 Years | Case Comprehensive Cancer Center | |
| Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma | NCT00800059 | Multiple Myelom... | Total Marrow Ir... | 18 Years - 60 Years | Ottawa Hospital Research Institute | |
| Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma | NCT01163357 | Autologous Hema... Loss of Chromos... Plasma Cell Leu... Recurrent Plasm... Refractory Plas... | bortezomib fludarabine pho... melphalan total marrow ir... tacrolimus sirolimus peripheral bloo... laboratory biom... | 18 Years - 70 Years | City of Hope Medical Center | |
| Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML | NCT02094794 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... | etoposide cyclophosphamid... total marrow ir... allogeneic hema... allogeneic bone... | 16 Years - 60 Years | City of Hope Medical Center | |
| Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma | NCT03100877 | Plasma Cell Leu... Plasma Cell Mye... | Autologous Hema... Cyclophosphamid... Filgrastim Laboratory Biom... Lenalidomide pheresis Melphalan Palifermin Total Marrow Ir... | 18 Years - 70 Years | City of Hope Medical Center | |
| Total Marrow Irradiation for Refractory Acute Leukemia | NCT00686556 | Acute Lymphobla... Myelodysplastic... Multiple Myelom... | cyclophosphamid... cyclosporine Fludarabine mycophenolate m... total marrow ir... umbilical cord ... Granulocyte col... HLA-matched rel... | - 55 Years | Masonic Cancer Center, University of Minnesota | |
| A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies | NCT05201183 | Acute Myeloid L... Chronic Myeloid... Acute Lymphocyt... Myelodysplastic... | Fludarabine + T... | 18 Years - | Indiana University | |
| 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome | NCT05139004 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... Secondary Acute... | Allogeneic Hema... Basiliximab Fludarabine Pho... Indium In 111-D... Melphalan Palifermin Total Lymphoid ... Total Marrow Ir... Yttrium Y 90 Ba... | 60 Years - | City of Hope Medical Center | |
| Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma | NCT00112827 | Refractory Mult... Smoldering Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | total marrow ir... melphalan peripheral bloo... filgrastim fluorescence in... cytogenetic ana... cyclophosphamid... autologous-auto... lenalidomide | - 70 Years | City of Hope Medical Center | |
| 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome | NCT05139004 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... Secondary Acute... | Allogeneic Hema... Basiliximab Fludarabine Pho... Indium In 111-D... Melphalan Palifermin Total Lymphoid ... Total Marrow Ir... Yttrium Y 90 Ba... | 60 Years - | City of Hope Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
